Literature DB >> 535132

Enhancement of methotrexate absorption by subdivision of dose.

W H Steele, J F Stuart, J R Lawrence, C A McNeill, W E Sneader, B Whiting, K C Calman, J G McVie.   

Abstract

A comparison was made in fasting patients between a single 100 mg oral dose of methotrexate formulated as its sodium salt in a palatable syrup and the same total quantity of drug administered in four divided doses of 25 mg taken at 2-h intervals. Allocation to the order of these treatment schedules was on a random basis. The area under the serum methotrexate concentration-time curve until 50 h was found to be considerably greater after the divided dose regimen, the mean ratio AUC 25 mg x 4/AUC 100 mg being 1.86 (+/- 0.90). There was no significant difference in peak serum methotrexate concentrations or methotrexate half-life estimates between the two regimens, however. The results of this study are consistent with saturation of an intestinal transport process when methotrexate is administered orally in a single large dose.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 535132     DOI: 10.1007/BF00254737

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Improved therapeutic index of methotrexate with "leucovorin rescue".

Authors:  M Levitt; M B Mosher; R C DeConti; L R Farber; R T Skeel; J C Marsh; M S Mitchell; R J Papac; E D Thomas; J R Bertino
Journal:  Cancer Res       Date:  1973-07       Impact factor: 12.701

2.  High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.

Authors:  G Rosen; S Suwansirikul; C Kwon; C Tan; S J Wu; E J Beattie; M L Murphy
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

3.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

4.  Pharmacokinetics of methotrexate.

Authors:  D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  The effect of organic acids on renal clearance of methotrexate in man.

Authors:  D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

6.  A rapid, sensitive and specific radioimmunoassay for methotrexate.

Authors:  J W Paxton; F J Rowell
Journal:  Clin Chim Acta       Date:  1977-11-01       Impact factor: 3.786

7.  Factors affecting the absorption of riboflavin in man.

Authors:  G Levy; W J Jusko
Journal:  J Pharm Sci       Date:  1966-03       Impact factor: 3.534

  7 in total
  9 in total

1.  Bioavailability of methotrexate: implications for clinical use.

Authors:  J F Stuart; K C Calman; J Watters; J Paxton; B Whiting; J R Lawrence; W H Steele; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 2.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

3.  The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle.

Authors:  V J Harvey; M L Slevin; R C Woollard; A Johnston; M J Barnett; P F Wrigley; P Turner
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Bioavailability of methotrexate tablets.

Authors:  J H Schornagel; M E Van Engelen; D De Vos
Journal:  Pharm Weekbl Sci       Date:  1982-06-25

5.  Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia.

Authors:  A D Pearson; S Mills; H A Amineddine; D R Long; A W Craft; J M Chessells
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 6.  Clinical pharmacokinetics of drugs used in the treatment of breast cancer.

Authors:  V J Wiebe; C C Benz; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

7.  Methotrexate in erythrocytes of patients with psoriasis.

Authors:  H Schrøder; E K Foged
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Effects of polysorbate 80 on the absorption and distribution of oral methotrexate (MTX) in mice.

Authors:  M N Azmin; J F Stuart; K C Calman; A T Florence
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.

Authors:  C R Pinkerton; S G Welshman; J G Kelly; R G Shanks; J M Bridges
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.